



Update Summary

Entity name

TRYPTAMINE THERAPEUTICS LIMITED

Announcement Type

Update to previous announcement

Date of this announcement

13/2/2025

Reason for update to a previous announcement

Updating for actual EGM date and therefore revised proposed issue date.

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

TRYPTAMINE THERAPEUTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ABN

Registration Number

78163765991

1.3 ASX issuer code

TYP

1.4 The announcement is

Update/amendment to previous announcement

1.4a Reason for update to a previous announcement

Updating for actual EGM date and therefore revised proposed issue date.

1.4b Date of previous announcement to this update

30/10/2024

1.5 Date of this announcement

13/2/2025

1.6 The Proposed issue is:

A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	20/3/2025	Actual	

Comments

EGM to be held on 20 March 2025, to

1. ratify the allotment under LR 7.1 in previously lodged App 3B
2. approve following allotment as per this App 3B
 - (A) LR 7.1, 87,500,000 shares and 112,500,000 options
 - (B) LR 7.1, 12m broker options
 - (C) LR 10.11,
 - a. Chris Ntoumenopoulos, being 10m shares and 5m options
 - b. Jason Carroll, being 15m shares and 7.5m options
 - c. Daniel Tillett, being 50m shares and 25m options

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

No

Details of +securities proposed to be issued

ASX +security code and description

TYP : ORDINARY FULLY PAID

Number of +securities proposed to be issued

162,500,000

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

Yes



In what currency is the cash consideration being paid?

AUD - Australian Dollar

What is the issue price per +security?

AUD 0.02000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

New class

Will the proposed issue of this +security include an offer of attaching +securities?

No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?

No

Will the entity be seeking quotation of the 'new' class of +securities on ASX?

No

ASX +security code

New class-code to be confirmed

+Security description

OPTION EXPIRING 2 YRS FROM ISSUE EX \$0.04

+Security type

Options

Number of +securities proposed to be issued

162,000,000

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

1. 150m options for capital raising, as announced on 30 October 2024, being one for two free attaching option, exercisable at \$0.04 expiring 2 years from issue date.
2. 12m broker options, exercisable at \$0.04 expiring 2 years from issue date.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

566,340.000000

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes



Options details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.0400	31/1/2027

Details of the type of +security that will be issued if the option is exercised

TYP : ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

1 TYP shares for each option exercised.

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

Refer ASX Release dated 30 October 2024.

Expiry date noted above is estimated and will be 2 years from actual issue date.

Part 7C - Timetable

7C.1 Proposed +issue date

31/3/2025

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

Yes

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

20/3/2025

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

Yes

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

Yes

7E.1a Who is the lead manager/broker?

Merchant Capital Partners Pty Ltd.



7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

1. a management and placement fee of 6.0%, plus GST of the total amount raised under any Capital Raising;
2. 12m unlisted options exercisable at 4.0 cents and expiring 2 years from issue date, subject to shareholder approval; and
3. Corporate Advisory and Marketing monthly retainer fee of \$5,000.00, plus GST per month for a term of 12-months commencing 1 October 2024 payable.

7E.2 Is the proposed issue to be underwritten?

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

1.Expanding:

- a) Phase 2 trial in Binge Eating Disorder TRP-8803: \$1.9m;
 - b) Phase 2 trial in Chronic Pain Fibromyalgia TRP-8803: \$1.9m;
- 2.GMP manufacturing of TRP-8803 to support clinical trials: \$750k;
- 3.Working cap: \$1,054k;
- 4.Costs of offer: \$396k.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

7F.2 Any other information the entity wishes to provide about the proposed issue

Number of shares and options is subject to rounding.

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a +disclosure document or +PDS involving the same class of securities as the +securities proposed to be issued that meets the requirements of section 708A(11) or 1012DA(11)